LivaNova PLC (LIVN) P/E Ratio History
UndervaluedTrading at 26.9x vs 5Y avg 178.7x · 22th percentile · Below historical baseline · Data 2017–2026
Loading P/E history...
P/E Ratio Analysis
As of November 18, 2026, LivaNova PLC (LIVN) trades at a price-to-earnings ratio of 26.9x, with a stock price of $91.92 and trailing twelve-month earnings per share of $3.42.
The current P/E is 85% below its 5-year average of 178.7x. Over the past five years, LIVN's P/E has ranged from a low of 21.9x to a high of 1034.8x, placing the current valuation at the 22th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.9x, LIVN is roughly in line with its sector peers. The sector includes 251 companies with P/E ratios ranging from 0.0x to 184.2x.
Relative to the broader market, LIVN commands a significant premium over the S&P 500 median P/E of 21.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LIVN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LIVN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
LIVN P/E vs Peers
Cardiovascular, Renal & Blood Devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 6.8Lowest | 0.66 | +817%Best | |
| $131B | 25.1 | 3.59 | +3% | |
| $182B | 38.7 | 4.68 | -51% | |
| $64B | 17.9 | - | +55% | |
| $122B | 33.7 | 2.27 | +8% | |
| $192M | 17.0 | 0.46Best | +51% | |
| $152B | 51.2 | 2.35 | +23% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
LIVN Historical P/E Data (2017–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $76.50 | $3.50 | 21.9x | -88% |
| FY2026 Q2 | - | $82.23 | $3.39 | 24.3x | -86% |
| FY2026 Q1 | - | $63.56 | $1.96 | 32.4x | -82% |
| FY2024 Q4 | - | $46.31 | $1.14 | 40.6x | -77% |
| FY2024 Q3 | Sep 30 2024 | $52.54 | $0.42 | 125.1x | -30% |
| FY2023 Q4 | Dec 31 2023 | $51.74 | $0.32 | 161.7x | -10% |
| FY2023 Q3 | Sep 30 2023 | $52.88 | $0.05 | 1034.8x | +479% |
| FY2017 Q3 | Sep 30 2017 | $70.06 | $1.17 | 59.9x | -66% |
| FY2017 Q2 | Jun 30 2017 | $61.21 | $0.57 | 107.8x | -40% |
Average P/E for displayed period: 178.7x
LIVN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LIVN — Frequently Asked Questions
Quick answers to the most common questions about buying LIVN stock.
What is LIVN's P/E ratio?
LivaNova PLC (LIVN) trailing twelve-month P/E ratio is 26.9x, based on TTM diluted EPS of $3.42. The 5-year average P/E is 178.7x and the historical range spans 21.9x to 1034.8x.
Is LIVN stock overvalued or undervalued?
LIVN trades at 26.9x P/E, below its 5-year average of 178.7x. At the 22th percentile of its historical range (21.9x–1034.8x), the stock is priced at a discount to its own history.
Is LIVN stock expensive?
No, LIVN is not expensive on a historical basis. The current P/E of 26.9x is below the 5-year average of 178.7x and sits at the 22th percentile of its valuation range.
What is LIVN's historical P/E range?
Over the past 5 years, LIVN's P/E ratio has ranged from 21.9x to 1034.8x, with a median of 59.9x and an average of 178.7x. The current P/E of 26.9x places the stock at the 22th percentile of this range. Full historical data spans 2017–2026.
How does LIVN's P/E compare to the S&P 500?
LIVN trades at 26.9x P/E versus the S&P 500 median of 21.5x. The 25% premium to the market typically reflects higher expected earnings growth or quality.
How does LIVN's valuation compare to Healthcare peers?
LivaNova PLC P/E of 26.9x compares to the Healthcare sector median of 24.9x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is LIVN's PEG ratio?
LIVN PEG ratio is N/A, based on a P/E of 26.9x and EPS growth of -483.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is LIVN's earnings yield?
LIVN earnings yield is 3.72%, the inverse of its 26.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.